EP1687029A4 - Neutralizing human antibodies to anthrax toxin generated by recall technology - Google Patents

Neutralizing human antibodies to anthrax toxin generated by recall technology

Info

Publication number: EP1687029A4
Authority: EP; European Patent Office
Prior art keywords: human antibodies; anthrax toxin; neutralizing human; toxin generated; recall
Prior art date: 2003-11-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP03816309A

Other languages

German (de)

French (fr)

Other versions

EP1687029A1 (en

Inventor

Phillip R Morrow

Angray S Kang

Fei Wang

Ivy Jiang

Ritsuko Sawada-Hirai

Wolfgang Scholz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Emergent Product Development Gaithersburg Inc

Original Assignee

Avanir Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-14

Filing date

2003-11-14

Publication date

2007-05-30

2003-11-14 Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc

2003-11-14 Priority to EP20120175602 priority Critical patent/EP2570433A1/en

2006-08-09 Publication of EP1687029A1 publication Critical patent/EP1687029A1/en

2007-05-30 Publication of EP1687029A4 publication Critical patent/EP1687029A4/en

Status Withdrawn legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1278—Bacillus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Immunology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EP03816309A 2003-11-14 2003-11-14 Neutralizing human antibodies to anthrax toxin generated by recall technology Withdrawn EP1687029A4 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP20120175602 EP2570433A1 (en)	2003-11-14	2003-11-14	Neutralizing human antibodies to anthrax toxin generated by recall technology

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2003/036555 WO2005056052A1 (en)	2003-11-14	2003-11-14	Neutralizing human antibodies to anthrax toxin generated by recall technology

Publications (2)

Publication Number	Publication Date
EP1687029A1 EP1687029A1 (en)	2006-08-09
EP1687029A4 true EP1687029A4 (en)	2007-05-30

Family

ID=34676210

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP20120175602 Withdrawn EP2570433A1 (en)	2003-11-14	2003-11-14	Neutralizing human antibodies to anthrax toxin generated by recall technology
EP03816309A Withdrawn EP1687029A4 (en)	2003-11-14	2003-11-14	Neutralizing human antibodies to anthrax toxin generated by recall technology

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP20120175602 Withdrawn EP2570433A1 (en)	2003-11-14	2003-11-14	Neutralizing human antibodies to anthrax toxin generated by recall technology

Country Status (5)

Country	Link
EP (2)	EP2570433A1 (en)
JP (1)	JP4690196B2 (en)
AU (1)	AU2003304600A1 (en)
CA (1)	CA2545714C (en)
WO (1)	WO2005056052A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7601351B1 (en)	2002-06-26	2009-10-13	Human Genome Sciences, Inc.	Antibodies against protective antigen
CA2560759A1 (en) *	2004-03-03	2005-12-22	Iq Corporation	Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
WO2007117264A2 (en) *	2005-08-03	2007-10-18	Fraunhofer Usa, Inc.	Compositions and methods for production of immunoglobulins
WO2008048344A2 (en)	2006-02-13	2008-04-24	Fraunhofer Usa, Inc.	Bacillus anthracis antigens, vaccine compositions, and related methods
US7794732B2 (en) *	2006-05-12	2010-09-14	Oklahoma Medical Research Foundation	Anthrax compositions and methods of use and production
EP2178558B1 (en)	2007-07-11	2014-04-30	iBio, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
US8784819B2 (en)	2009-09-29	2014-07-22	Ibio Inc.	Influenza hemagglutinin antibodies, compositions and related methods
US20200158729A1 (en) *	2017-06-06	2020-05-21	Indevr, Inc.	Simultaneous in vitro analysis of vaccine potency and toxin concentration

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0779795A (en) *	1993-07-21	1995-03-28	Takeda Chem Ind Ltd	Method for producing human monoclonal antibody-producing strain
US20020001798A1 (en) *	1995-06-07	2002-01-03	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5476996A (en)	1988-06-14	1995-12-19	Lidak Pharmaceuticals	Human immune system in non-human animal
JP2981486B2 (en) *	1988-06-14	1999-11-22	メディカル・バイオロジー・インスティチュート	Mammalian immune system research methods
US6329156B1 (en) *	1999-03-22	2001-12-11	The Regents Of The University Of California	Method for screening inhibitors of the toxicity of Bacillus anthracis
JP2006503547A (en) *	2002-02-11	2006-02-02	アレクシオンファーマシューティカルズ，インコーポレイテッド	Immunotherapy for biological weapons defense

2003
- 2003-11-14 JP JP2005511724A patent/JP4690196B2/en not_active Expired - Fee Related
- 2003-11-14 CA CA2545714A patent/CA2545714C/en not_active Expired - Fee Related
- 2003-11-14 WO PCT/US2003/036555 patent/WO2005056052A1/en not_active Ceased
- 2003-11-14 EP EP20120175602 patent/EP2570433A1/en not_active Withdrawn
- 2003-11-14 EP EP03816309A patent/EP1687029A4/en not_active Withdrawn
- 2003-11-14 AU AU2003304600A patent/AU2003304600A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0779795A (en) *	1993-07-21	1995-03-28	Takeda Chem Ind Ltd	Method for producing human monoclonal antibody-producing strain
US20020001798A1 (en) *	1995-06-07	2002-01-03	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. KEARNEY ET AL.: "A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.", THE JOURNAL OF IMMUNOLOGY, vol. 123, no. 4, October 1979 (1979-10-01), pages 1548 - 1550, XP001194440 *
LITTLE S F ET AL: "Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin.", INFECTION AND IMMUNITY JUL 1988, vol. 56, no. 7, July 1988 (1988-07-01), pages 1807 - 1813, XP002959465, ISSN: 0019-9567 *
See also references of WO2005056052A1 *

Also Published As

Publication number	Publication date
CA2545714C (en)	2012-10-16
JP4690196B2 (en)	2011-06-01
JP2007525145A (en)	2007-09-06
EP1687029A1 (en)	2006-08-09
EP2570433A1 (en)	2013-03-20
CA2545714A1 (en)	2005-06-23
WO2005056052A1 (en)	2005-06-23
AU2003304600A1 (en)	2005-06-29

Legal Events

Date	Code	Title	Description
2006-07-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-08-09	17P	Request for examination filed	Effective date: 20060428
2006-08-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
2007-02-21	DAX	Request for extension of the european patent (deleted)
2007-05-30	A4	Supplementary search report drawn up and despatched	Effective date: 20070427
2008-07-09	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
2010-08-04	17Q	First examination report despatched	Effective date: 20100702
2012-05-23	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/12 20060101AFI20120417BHEP Ipc: A61K 39/40 20060101ALI20120417BHEP Ipc: A61K 39/395 20060101ALI20120417BHEP Ipc: C12P 21/08 20060101ALI20120417BHEP Ipc: A61P 31/04 20060101ALI20120417BHEP Ipc: C07K 16/00 20060101ALI20120417BHEP
2012-07-09	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2013-04-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2013-05-22	18D	Application deemed to be withdrawn	Effective date: 20121120

Publication	Publication Date	Title
PL373886A1 (en)	2005-09-19	Neutralizing human anti-igfr antibody
IL218892A0 (en)	2012-05-31	Human anti-b7rp1 neutralizing antibodies
TWI365883B (en)	2012-06-11	Antibodies to m-csf
IL191340A (en)	2015-08-31	Human monoclonal antibodies to o8e
EP1591527A4 (en)	2006-05-24	Substance specific to human pd-1
IL189788A0 (en)	2008-08-07	Human monoclonal antibodies to cd70
GB0320283D0 (en)	2003-10-01	Improvements relating to lancets
EP1648509B8 (en)	2012-10-24	Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
SI2813338T1 (en)	2016-12-30	Methods to produce gel sheets
EP1494714A4 (en)	2008-03-05	Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
IL173273A0 (en)	2006-06-11	Modified human igf-1r antibodies
AU2003295411A1 (en)	2004-06-03	Human monoclonal antibodies to heparanase
ZA200802641B (en)	2009-02-25	Human monoclonal antibodies to CD70
EP1687029A4 (en)	2007-05-30	Neutralizing human antibodies to anthrax toxin generated by recall technology
GB0305363D0 (en)	2003-04-16	Improvements relating to skin prickers
IL172511A0 (en)	2006-04-10	Specific human antibodies
ZA200804254B (en)	2009-01-28	Human monoclonal antibodies to O8E
HK1067893A (en)	2005-04-22	Neutralizing human anti-igfr antibody
HK1122825A (en)	2009-05-29	Human monoclonal antibodies to o8e
EP1560595A4 (en)	2005-12-28	Fully human antibody fab fragments with human interferon-gamma neutralizing activity
HK1114106A (en)	2008-10-24	Human monoclonal antibodies to cd70
GB0300454D0 (en)	2003-02-12	Human excrement collector
GB0325391D0 (en)	2003-12-03	Human monoclonal antibodies
SI1656391T1 (en)	2010-12-31	Modified human igf-1r antibodies
GB0502201D0 (en)	2005-03-09	Human antibodies